Friday, July 10, 2026

pharma · Pompe Disease (Late-onset) · Fabry Disease

Pacalis Therapeutics Pty

AMICUS THERAPEUTICS PTY is a pharma organization headquartered in AU. Primary therapeutic focus areas include Pompe Disease (Late-onset), Fabry Disease, Fabry disease. NovaPharmaNews links 5 clinical program(s), 1 drug p

melbourne, AU HQ
2023 Founded
1 Employees
TGA registrant Type
Company details
Status
Public
HQ
melbourne, AU
Founded
2023
Employees
1
Programs
5
Drugs
6
Patents
0
Clinical program

Migalastat Hydrochloride Dispersible Tablet

Phase 3 · small molecule · Fabry disease

Migalastat Hydrochloride Dispersible Tablet for Fabry disease is a Phase 3 program (small_molecule) at AMICUS THERAPEUTICS PTY LTD with 1 ClinicalTrials.gov record(s).

Internal code AT1001-033

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
AMICUS THERAPEUTICS PTY LTD
Phase
Phase 3
Modality
small_molecule
Indication
Fabry disease
Status
active
Trials
1